902452-83-9

Upstream product

• 108-24-7 acetic anhydride 
• 206055-71-2 1-[(1R,4R,6R,7S)-4-[[bis(4-methoxyphenyl)phenylmethoxy]methyl]-7-hydroxy-2,5-dioxabicyclo[2.2.1]heptan-6-yl]-5-methylpyrimidine-2,4-dione 
• 63593-03-3 1,2-O-isopropylidene-3-O-benzyl-4-hydroxymethyl-α-D-ribofuranose 
• 293751-01-6 3-O-benzyl-4-C-methanesulfonoxymethyl-5-methanesulfonyl-1,2-O-isopropylidene-α-D-erythro-pentofuranose 
• 293751-03-8 1,2-di-O-acetyl-3-O-benzyl-4-C-methanesulfonyloxymethyl-5-O-methanesulfonyl-D-erythro-pentofuranose 
• 40615-36-9 4,4'-dimethoxytrityl chloride 
• 206055-67-6 (1S,3R,4R,7S)-7-hydroxy-1-hydroxymethyl-(thymin-1-yl)-2,5-dioxabicyclo[2.2.1]heptane 
• 22331-21-1 1,2:5,6-di-O-isopropylidene-3-O-benzyl-α-D-allofuranose 
• 57099-04-4 3-O-benzyl-1,2-O-isopropylidene-α-D-allofuranose 
• 582-52-5 1,2:5,6-di-O-isopropylidene-α-D-glucofuranose 
• 2847-00-9 1,2:5,6-di-O-isopropylidene-α-D-hexofuran-3-ulose 
• 212970-84-8 (1S,3R,4R,7S)-7-benzyloxy-1-hydroxymethyl-3-(thymin-1-yl)-2,5-dioxabicyclo[2.2.1]heptane 
• 293751-04-9 1-(2-O-acetyl-3-O-benzyl-4-C-methanesulfonyloxymethyl-5-O-methanesulfonyl-β-D-erythro-pentofuranosyl)thymine 

Downstream Products

• 902452-85-1 1-[3-O-acetyl-5-O-(4,4'-dimethoxytrityl)-2-O,4-C-methylene-β-D-ribofuranosyl]-5-methyl-4-(1,2,4-triazol-1-yl)-2-oxypyrimidine 
• 206055-82-5 (1R,3R,4R,7S)-3-(4-N-benzoyl-5-methylcytosin-1-yl)-[2-cyanoethoxy(diisopropylamino)phosphinoxy]-1-[4,4'-dimethoxytrityloxymethyl]-2,5-dioxabicyclo[2.2.1]heptane 
• 1449203-61-5 1-(5-O-(4,4'-dimethoxytrityl)-2-O,4-C-methylene-β-D-ribofuranosyl)-4-[(3S)-3-aminopyrrolidin-1-yl]-5-methylpyrimidin-2-one 
• 1449203-62-6 C₄₅H₄₈N₈O₁₁ 
• 1449203-63-7 C₅₄H₆₅N₁₀O₁₂P 
• 1449203-59-1 1-(3-O-acetyl-5-O-(4,4'-dimethoxytrityl)-2-O,4-C-methylene-β-D-ribofuranosyl)-4-O-(2,4,6-triisopropylphenylsulfonyl)thymine 

Relevant academic research and scientific papers

Towards the enzymatic synthesis of phosphorothioate containing LNA oligonucleotides

Therapeutic oligonucleotides require the addition of multiple chemical modifications to the nucleosidic scaffold in order to improve their drug delivery efficiency, cell penetration capacity, biological stability, and pharmacokinetic properties. This chem

NOVEL PROCESS FOR MAKING ALLOFURANOSE FROM GLUCOFURANOSE

The present invention relates to the manufacture of allofuranose from glucofuranose as defined in the description and in the claim. Allofuranos is an intermediate in the manufacture of oligonucleotides which can be used as a medicament.

5′- vs. 3′-end sugar conformational control in shaping up dinucleotides

The 5′-end N-sugar puckering is currently believed to govern the intramolecular dinucleotide stacking. We demonstrate that if this 5′-conformation is indeed important in shaping up dinucleotide structures, the 3′-end sugar conformation can either potentia

Conformationally restricted triplex-forming oligonucleotides (TFOs). Binding properties of α-l-LNA and introduction of the N7-glycosylated LNA-guanosine

The method for scaled-up production of α-l-LNA phosphoramidite building blocks containing thymine and 5-methylcytosine nucleobases is described. Binding properties of pyrimidine TFOs modified with α-l-LNA are reported. In contrast to LNA TFOs, the fully m